Tenaya Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
171 Oyster Point Blvd Ste 500, South San...Phone Number
(650) 825-6990Website
www.tenayatherapeutics.comRevenue
<$5 MillionStock Symbol
TNYAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies and precision medicines for genetic heart diseases. The company leverages human genetics, viral vector engineering, and cellular models to design potentially curative treatments for cardiomyopathies such as hypertrophic and arrhythmogenic cardiomyopathy, aiming to address the underlying causes of heart failure.Explore more
Tenaya Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tenaya Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Tenaya Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Tenaya Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Tenaya Therapeutics recently announced quarterly report
Product Launch: Get notified when Tenaya Therapeutics launches new products
Funding: Get notified immidiatlly once Tenaya Therapeutics has new funding data
Check if Tenaya Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Tenaya Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Tenaya Therapeutics
Recommended Actions
Reach out to Masked Content who joined Tenaya Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Tenaya Therapeutics
Compare insights from companies similar to Tenaya Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tenaya Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Tenaya Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Tenaya Therapeutics.
Tenaya Therapeutics financials insights
Gather financial insights about Tenaya Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$50M
2019
Series B
$92M
2021
Series C
$106M
Share Placement
$180M
Tenaya Therapeutics Tech Stack
A closer look at the technologies used by Tenaya Therapeutics
See more technologies
Most Recent Scoops
Project
Tenaya Therapeutics is currently conducting toxicology work and Phase II study design for TN-301, with plans to announce the Phase II program details in Q4 and initiate Phase II in the second half of next year.
Medical Research, Clinical Operations
Project
Tenaya Therapeutics has announced the reintroduction of TN-301, its HDAC6 inhibitor small molecule program, following the completion of Phase I and encouraging preclinical data, citing increased activity in the broader HDAC inhibition space and its potential in heart failure and related indications.
Medical Research, Pharmaceuticals
Project
Tenaya Therapeutics has reported that the Phase I study of TN-301, conducted in 72 patients, demonstrated a favorable safety and tolerability profile, confirmed target engagement, and a pharmacokinetic/pharmacodynamic profile consistent with once-daily dosing, supporting advancement into Phase II.
Pharmaceuticals, Clinical Operations
Project
Tenaya Therapeutics has initiated a pediatric natural history study for TN-201 to characterize disease progression in younger patients with MYBPC3-associated HCM, with findings intended to inform future regulatory endpoint discussions and a potential pediatric development path.
Person-Based
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tenaya Therapeutics
Sign Up For FreeTo access detailed company insights
Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies and precision medicines for genetic heart diseases. The company leverages human genetics, viral vector engineering, and cellular models to design potentially curative treatments for cardiomyopathies such as hypertrophic and arrhythmogenic cardiomyopat... Read More
